Fulgent Genetics Stock Earnings Reports

Key points for investors:

- Financials: Q1 2026 revenue was $71.1M (down vs. prior quarter), driven primarily by lower volume from the company's largest customer transitioning testing in‑house and some claims/timing effects. GAAP gross margin was 30.2% and non‑GAAP gross margin was 32.3%. GAAP loss was $24.8M. Adjusted EBITDA was a loss of ~$15.2M. Q1 included $2.6M revenue from the recently closed Bako Diagnostics and StrataDx acquisition. Cash, cash equivalents, restricted cash and marketable securities were ~$604.7M at quarter end (down ~$100.8M vs. prior quarter driven by the acquisitions and share repurchases).

- Guidance and capital allocation: Management reiterated full‑year 2026 revenue guidance of $350M (≈+8.5% YoY). They updated non‑GAAP EPS guidance to a loss of $1.59 per share (reflecting a lower share count from aggressive buybacks). They expect non‑GAAP gross margins ~39% for the year with improvement to ~42% by year‑end and non‑GAAP operating margin of about -20% for 2026. The company has repurchased ~3.1M shares YTD and has ~ $91M remaining under the repurchase authorization. The cash projection assumes receipt of a delayed ~$106M tax refund.

- M&A / Commercial: Completion of the Bako Diagnostics and StrataDx acquisitions more than doubles the pathology sales team and is expected to contribute ~ $53M annualized to revenue in the back half of 2026, improving customer concentration (no single customer >10% of revenue expected for full year). Integration and cross‑training are top priorities. Q2+ quarterly targets are expected to be higher, with quarterly revenue targets in excess of ~$90M in later quarters.

- Lab operations & product innovation: AI and digital pathology investments are accelerating operational improvements (EasioPath platform now ~100% visual across cases). New product advances: expanded whole genome test (Illumina TruPath Genome proximity mapping to capture complex SVs, repeat expansions, phasing, etc.) and rollout of a dermatopathology AI auto‑rotation tool to speed and standardize slide review. MolDX approval and pricing were received for their pharmacogenomics (PGx) test (notably DPYD), positioning Fulgent to capture near‑term oncology PGx demand as guidelines (ASCO/NCCN/FDA) shift toward DPYD testing.

- Therapeutics (FID pipeline): Therapeutic R&D is progressing: FID‑007 completed Phase II enrollment (46 patients), early data described as encouraging (combination with Cetuximab showing meaningful anticancer activity and favorable tolerability). An ASCO rapid oral presentation was accepted; management expects an end‑of‑Phase II meeting with FDA in H2 2026 and hopes to start a Phase III registration trial in H1 2027. FID‑022 (nanoencapsulated SN‑38) is in Phase I dose escalation (DL3 completed; DL4 ongoing), with a plan to determine MTD later in 2026. Management says pharma R&D spend for 2026 is expected to be ~ $26M.

- Risks / near‑term dynamics: Q1 softness included seasonality and weather impacts; Biopharma Services remains lumpy with long sales cycles; recovery in margins and volume depends on backlog normalization, stabilization of largest customer volumes, and full integration of acquisitions. The company emphasizes significant cash runway and flexibility to self‑fund trials but remains open to strategic partnerships for therapeutics.